Compare, Analyse Aurobindo Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ACTAVIS (US) - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   ACTAVIS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
ACTAVIS
Dec-18
AUROBINDO PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs83014,106-   
Low Rs5279,462-   
Sales per share (Unadj.) Rs333.93,460.2-  
Earnings per share (Unadj.) Rs40.4-1,114.5-  
Cash flow per share (Unadj.) Rs51.8364.6-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs237.114,271.8-  
Shares outstanding (eoy) m585.91332.60-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.03.4 59.7%   
Avg P/E ratio x16.8-10.6 -159.0%  
P/CF ratio (eoy) x13.132.3 40.6%  
Price / Book Value ratio x2.90.8 346.6%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m397,5693,919,453 10.1%   
No. of employees `00017.916.9 105.7%   
Total wages/salary Rs m25,8490-   
Avg. sales/employee Rs Th10,956.968,099.0 16.1%   
Avg. wages/employee Rs Th1,447.70-   
Avg. net profit/employee Rs Th1,324.3-21,934.7 -6.0%   
INCOME DATA
Net Sales Rs m195,6361,150,872 17.0%  
Other income Rs m1,55322,009 7.1%   
Total revenues Rs m197,1891,172,881 16.8%   
Gross profit Rs m39,51930,159 131.0%  
Depreciation Rs m6,680491,973 1.4%   
Interest Rs m2,62666,412 4.0%   
Profit before tax Rs m31,767-506,218 -6.3%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881129,106 -0.7%   
Tax Rs m7,269-6,415 -113.3%   
Profit after tax Rs m23,645-370,697 -6.4%  
Gross profit margin %20.22.6 770.9%  
Effective tax rate %22.91.3 1,805.5%   
Net profit margin %12.1-32.2 -37.5%  
BALANCE SHEET DATA
Current assets Rs m153,645472,028 32.6%   
Current liabilities Rs m120,429417,571 28.8%   
Net working cap to sales %17.04.7 358.8%  
Current ratio x1.31.1 112.9%  
Inventory Days Days13520 690.3%  
Debtors Days Days6466 96.1%  
Net fixed assets Rs m103,909130,272 79.8%   
Share capital Rs m5860-   
"Free" reserves Rs m138,3220-   
Net worth Rs m138,9084,746,811 2.9%   
Long term debt Rs m1,8001,671,524 0.1%   
Total assets Rs m264,5447,420,345 3.6%  
Interest coverage x13.1-6.6 -197.8%   
Debt to equity ratio x00.4 3.7%  
Sales to assets ratio x0.70.2 476.8%   
Return on assets %9.9-4.1 -242.2%  
Return on equity %17.0-7.8 -218.0%  
Return on capital %23.8-4.8 -492.4%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Net fx Rs m56,7270-   
CASH FLOW
From Operations Rs m16,220411,163 3.9%  
From Investments Rs m-28,768225,881 -12.7%  
From Financial Activity Rs m19,191-705,679 -2.7%  
Net Cashflow Rs m6,656-68,293 -9.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 72.9 Rs / USD

Compare AUROBINDO PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: NEULAND LABS  GSK PHARMA  FRESENIUS KABI ONCO.  ABBOTT INDIA  STRIDES PHARMA SCIENCE  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views On News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

AUROBINDO PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

FEATURED VIDEOS

A Time Correction in the Nifty

The Best Stocks in a Volatile Market

Gold 65,000 and Silver 84,000 in 2022

How Long Before a Big Stock Market Crash

More Featured Videos

MARKET STATS